Utility of NGS Assays for the Evaluation of Lymphoid Malignancies – Webinar
This webinar will explore how insights gained through NGS translate to the development of improved treatment of lymphoid malignancies.
25Feb
News
06Sep
Study Reviewing 2,500 Performed Idylla Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods
Press Release: Mechelen, Belgium, 27 June 2018
11Jun
Study Demonstrates Ability of Idylla EGFR Mutation Test to Produce a Result in 80% of Failed Next Generation Sequencing Lung Cancer Tests
A new publication in the Journal of Clinical Pathology demonstrated that the Idylla EGFR Mutation Test (CE-IVD) was able to rescue 80% of the EGFR samples whose assessment was unsuccessful with Next Generation Sequencing (NGS).
11May
Join Invivoscribe at EHA 2018
Planning on attending EHA 2018 in Sweden?
Invivoscribe invites to you attend a dinner social. Hear about ‘Minimal Residual Disease in Multiple Myeloma by NGS: A Comparison with Flow Cytometry’.
24Feb
New Products from Invivoscribe
Minimal Residual Disease (MRD) testing by Next Generation Sequencing (NGS) has become an important methodology demonstrating clear potential to optimize therapeutic management of lymphoproliferative diseases.